ArticleTranslational cancer research2026
Comprehensive analysis identifies PKMYT1 as an oncogene and potential prognostic and immunological biomarker in lung adenocarcinoma.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The microRNA Expression Signature of Lung Adenocarcinoma HarboringInternational journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lung adenocarcinoma (LUAD) remains a leading cause of cancer-related mortality, underscoring the urgent need for novel prognostic biomarkers and therapeutic targets. Although PKMYT1, a serine/threonine protein kinase, is implicated in cell cycle regulation, its comprehensive role and clinical significance in LUAD remain poorly defined. This study aims to investigate the oncogenic function, prognostic value, and immunomodulatory role of Methods: We performed integrated multi-omics analyses utilizing data from The Cancer Genome Atlas and Gene Expression Omnibus databases. Differential expression, survival, and immune cell infiltration analyses were conducted. Functional enrichment was assessed via Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathways. Drug sensitivity was predicted in silico. Results: Conclusions: This study establishes
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.